logo

MEA Cancer Vaccines Market Size (2024 - 2029)

The Middle East and Africa cancer vaccine market is anticipated to experience significant growth over the forecast period, driven by an increase in cancer cases and advancements in vaccine research and development. The market's expansion is supported by strategic activities such as partnerships and mergers, which enhance product availability. Despite the challenges posed by the COVID-19 pandemic, which delayed vaccine development and affected screening programs, the market is poised for growth as restrictions ease. However, the adoption of alternative cancer treatment therapies may pose a challenge to this growth trajectory.

Home Market Analysis Healthcare Research Pharmaceuticals Research Finished Dosage Form Research Vaccines Research MEA Cancer Vaccines Market Market Size

Market Size of MEA Cancer Vaccines Industry

MEA Cancer Vaccines Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Historical Data Period 2019 - 2022
CAGR 9.60 %
Market Concentration Medium

Major Players

MEA Cancer Vaccines Market Major Players

*Disclaimer: Major Players sorted in no particular order

MEA Cancer Vaccines Market Analysis

The Middle East and Africa cancer vaccine market is expected to register a CAGR of 9.6% during the forecast period.

  • COVID-19 significantly impacted the Middle East and African cancer vaccine market since there occurred a delay in the development and availability of cancer vaccines in the studied region due to the lockdown restrictions. As per the article published in October 2021 in PubMed, to make the best use of the limited resources for cancer management in COVID-19 epidemic settings, oncology centers and institutes across the region created clinical practice guidelines and recommendations.
  • Additionally, the pandemic affected African cancer screening and diagnostic programs. Cancer screening programs (including mammograms and pap smears) were discontinued in Morocco due to the early rise in COVID-19 cases. However, as the restrictions are lifted, and the pandemic spread reduced, the cancer vaccine market in the Middle East and Africa is expected to witness significant growth due to the rise in cancer cases and the increase in research development in cancer vaccines.
  • Factors such as the high prevalence of cancer cases, the increase in cancer vaccine development, and the rise in demand for cancer vaccines across the region are expected to drive market growth. According to IARC estimations, the number of new cancer cases in Africa is estimated to be 1.5 million by 2030. This number is likely to rise to 2.1 million by 2040.
  • Furthermore, strategic activities like partnerships, acquisitions, and mergers by key players are expected to increase product availability, which is likely to drive market growth over the forecast period. For instance, in February 2022, Pfizer renewed its partnerships with United Arab Emirates-based cancer patient societies Friends of Cancer Patients (FOCP) and Emirates Oncology Society to mark World Cancer Day. The pharmaceutical company has reinforced its commitment to advance oncology care, encourage early detection, and support cancer treatment in the country.
  • Further, in January 2022, South African-born United States billionaire Patrick Soon-Shiong and South African President Cyril Ramaphosa opened a new vaccine manufacturing plant for cancer and COVID-19 vaccine in Cape Town. It aimed to hasten the domestic production of pharmaceuticals and vaccines that will reach patients across the African continent.
  • Hence, considering the high prevalence of cancer cases and the increase in strategic activities by the key players, the studied market is expected to witness fair growth over the forecast period. However, adopting alternative therapies in cancer treatment is expected to hinder market growth.

MEA Cancer Vaccines Industry Segmentation

As per the scope of the report, cancer vaccines are defined as vaccines developed to prevent or treat existing cancers by strengthening the body's natural immune response system against cancer. These cancer vaccines belong to a class of substances known as biological response modifiers.

The Middle East and Africa cancer vaccine market is segmented by technology (recombinant cancer vaccines, whole-cell cancer vaccines, viral vector & DNA cancer vaccines, other technologies), treatment method (preventive vaccine and therapeutic vaccine), application (prostate cancer, cervical cancer, other applications) and geography (GCC, South Africa, Rest of Middle East and Africa).

The report offers the value (in USD million) for the above segments.

By Technology
Recombinant Cancer Vaccines
Whole-cell Cancer Vaccines
Viral Vector and DNA Cancer Vaccines
Other Technologies
By Treatment Method
Preventive Vaccine
Therapeutic Vaccine
By Application
Prostate Cancer
Cervical Cancer
Other Applications
Geography
GCC
South Africa
Rest of Middle East and Africa
Need A Different Region Or Segment?
Customize Now

MEA Cancer Vaccines Market Size Summary

The Middle East and Africa cancer vaccines market is poised for significant growth, driven by the increasing prevalence of cancer cases and the rising demand for cancer vaccines. The market is expected to expand steadily over the forecast period, supported by advancements in research and development activities. The COVID-19 pandemic initially disrupted the market by delaying vaccine development and affecting cancer screening programs. However, as restrictions ease, the market is anticipated to recover and grow, bolstered by strategic initiatives such as partnerships, acquisitions, and mergers by key industry players. These efforts aim to enhance product availability and support the development of innovative cancer vaccines across the region.

In the Gulf Cooperation Council (GCC) region, the market is further propelled by government initiatives and investments in healthcare, alongside a growing focus on research and novel therapeutics. The introduction of HPV vaccines and increased awareness campaigns are expected to drive the cervical cancer vaccine segment's growth. Despite challenges such as the adoption of alternative therapies, the market's expansion is supported by collaborations and the establishment of new healthcare facilities. Key players like AstraZeneca, Merck & Co., and GlaxoSmithKline are actively engaging in strategies to strengthen their market presence, contributing to the overall growth trajectory of the cancer vaccines market in the Middle East and Africa.

Explore More

MEA Cancer Vaccines Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increasing Number of Cancer Cases

      2. 1.2.2 Rise in Research and Developments in Cancer Vaccines

    3. 1.3 Market Restraints

      1. 1.3.1 Presence of Alternative Therapies

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size - Value in USD million)

    1. 2.1 By Technology

      1. 2.1.1 Recombinant Cancer Vaccines

      2. 2.1.2 Whole-cell Cancer Vaccines

      3. 2.1.3 Viral Vector and DNA Cancer Vaccines

      4. 2.1.4 Other Technologies

    2. 2.2 By Treatment Method

      1. 2.2.1 Preventive Vaccine

      2. 2.2.2 Therapeutic Vaccine

    3. 2.3 By Application

      1. 2.3.1 Prostate Cancer

      2. 2.3.2 Cervical Cancer

      3. 2.3.3 Other Applications

    4. 2.4 Geography

      1. 2.4.1 GCC

      2. 2.4.2 South Africa

      3. 2.4.3 Rest of Middle East and Africa

MEA Cancer Vaccines Market Size FAQs

The MEA Cancer Vaccines Market is projected to register a CAGR of 9.60% during the forecast period (2024-2029)

AstraZeneca PLC, Merck & Co. Inc., Bristol-Myers Squibb, Astellas Pharma Inc. and GSK plc are the major companies operating in the MEA Cancer Vaccines Market.

MEA Cancer Vaccines Market Report Snapshots

Middle-East and Africa Cancer Vaccines Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)